Medpace

About Medpace

Medpace Holdings, Inc. operates as a global Contract Research Organization (CRO), providing comprehensive clinical development services for the pharmaceutical, biotechnology, and medical device industries. The company was founded in Cincinnati, Ohio, in 1992 by Dr. August J. Troendle, who continues to lead as CEO and Chairman of the Board. Dr. Troendle's background as a medical review officer at the U.S. Food and Drug Administration (FDA) and his experience in clinical development at Sandoz (now Novartis) provided a unique perspective into the drug development process, shaping the company's physician-led, scientifically-driven approach.

The firm's business model is centered on providing full-service, integrated support for Phase I-IV clinical trials. This end-to-end approach means Medpace manages the entire clinical trial process, from study design and regulatory submissions to clinical monitoring, data management, and final reporting. Revenue is generated by providing these services to clients, who are primarily small to mid-sized biotechnology companies that often lack the internal resources to conduct complex trials independently. The company's full-service outsourcing model is designed to increase efficiency and quality by having one dedicated team manage all aspects of a trial, reducing the need for sponsors to oversee multiple vendors.

Medpace's service portfolio is extensive, encompassing study management, regulatory strategy, patient recruitment, biostatistics, medical writing, and quality assurance. A key differentiator is its ownership of integrated laboratory services, including global central labs, a bioanalytical lab, and imaging and ECG core labs. This vertical integration allows for streamlined processes and data consistency throughout a clinical study. The company serves a global market with operations in over 40 countries across North America, Europe, and the Asia-Pacific region. After a period of private ownership, Medpace became a publicly traded company in August 2016, listing on the Nasdaq under the ticker symbol MEDP.